| Name | Title | Contact Details |
|---|---|---|
Heather Hall |
CIO / IT Director | Profile |
AmeriVet Veterinary Partners is a company dedicated to supporting veterinary practices across the United States. Founded in 2016 and based in San Antonio, Texas, AmeriVet provides a range of business solutions that allow veterinary clinics to focus on animal care while benefiting from the companys resources and expertise. The services offered by AmeriVet include operational support, marketing strategies, professional training programs, human resources assistance, and financial management tools. These services are designed to enhance the efficiency and profitability of veterinary practices. AmeriVet operates on a partnership model, offering joint venture and full acquisition options that enable practice owners to maintain a stake in their business while accessing comprehensive support. With reported revenue of $205.5 million and significant funding, AmeriVet is recognized as a leading partner for veterinary clinics nationwide. The company has also been acknowledged as one of the top places to work in 2023, reflecting its commitment to a positive work environment for employees.
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.
LJUNGSTRÖM is a historic company with over 100 years of expertise in advanced environmental solutions, focusing on heat recovery and emissions control. Founded in 1923 by Fredrik Ljungström, the company is known for inventing the worlds first air preheater, which significantly improved energy efficiency in power plants. Today, LJUNGSTRÖM is a global leader in industrial flue gas management technologies and custom-engineered assemblies. The company offers a range of products, including its flagship Ljungström air preheater, which enhances thermal efficiency in steam power plants by recovering waste heat from flue gases. Additionally, LJUNGSTRÖM provides gas-gas heaters that further improve plant efficiency and custom-engineered solutions for emissions control. Their services aim to optimize plant performance and reduce CO₂ emissions, contributing to sustainability in the energy and industrial sectors. LJUNGSTRÖM serves a diverse international customer base across more than 100 countries, focusing on power generation plants and industrial facilities. The company is committed to innovation, operational excellence, and environmental sustainability, aiming to lead the industry in energy efficiency and impact.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.